News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)
-Single-Dose Antibiotic with One-Hour Infusion, Additional Compatibilities in Normal Saline and D5W, and Lower Infusion Volume-
Melinta Therapeutics Announces Appointment Of Susan Blum As Chief Financial Officer
Melinta Therapeutics Announces Appointment Of Susan Blum As Chief Financial Officer
Melinta Therapeutics, LLC (“Melinta”), a commercial-stage company focused on the development and commercialization of novel...
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin)
Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin)
The efficacy and safety of KIMYRSA were established in the SOLO clinical trials with another oritavancin product, ORBACTIV®...